Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- 303 Orphan Drugs under Development in US
September 24, 2007
- Boehringer Ingelheim Ties Up with Ablynx for Nanobody Therapeutics
September 24, 2007
- Takara Bio Licenses Anticancer Immunotherapy to Korean Company
September 24, 2007
- Nihon Medi-Physics, Nippon Kayaku to Handle Metastron of GE Healthcare
September 24, 2007
- Environment Assuring Rapid Supply of New Anticancer Drugs Needed
September 24, 2007
- NBI Moves Its Tokyo Office to Osaki
September 24, 2007
- Development of New PPAR Agonists Extremely Difficult: Dr Obayashi
September 24, 2007
- Innovex, So-net M3 to Provide MR Activities Assessing Service
September 24, 2007
- Need to Legalize GL on Clinical Research Stressed by Committee Members
September 24, 2007
- Kyowa Hakko Recalls Coniel Tab due to Contamination Problem
September 24, 2007
- R&D NEWS IN BRIEF
September 24, 2007
- BUSINESS NEWS IN BRIEF
September 24, 2007
- OPINION／Secrets behind a Winning Recruitment Team
September 24, 2007
- TOPICS／Banyu Most Often Comes to Mind for its Female MRs: Nextit Survey
September 24, 2007
- FY2007 Annual Report on Health and Welfare Published
September 24, 2007
- Korosho to Enhance Quality Surveillance System for Generics
September 24, 2007
- 24.7 Million Units of Influenza Vaccines to Be Supplied for Next Season
September 24, 2007
- GENERICS NEWS IN BRIEF
September 24, 2007
- European GL on Hypertension, Coronary Artery Disease Revised
September 24, 2007
- Taiyo's Tablet Production Capacity Up to 8.5 Bil. Per Year
September 17, 2007
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…